Search NASA⌕ Search

Engineering topics

Kry, S

Publications and source records attributed to Kry, S.

27 records · Page 2

MO-G-BRE-02: A Survey of IMRT QA Practices for More Than 800 Institutions

Purpose: A wide range of techniques and measurement devices are employed for IMRT QA, causing a large variation of accepted action limits and potential follow up for failing plans. Such procedures are not well established or accepted in the medical physics community. To achieve the goal of proving insight into current IMRT QA practices, we created an electronic IMRT QA survey. The survey was open to a variety of the most common QA devices and assessed the type of comparison to measurement, action limits, delivery methods, and clinical action for failing QA plans. Methods: We conducted an online survey through the Radiological Physics Center's (RPC) annual survey with the goal of ascertaining elements of routine patient-specific IMRT QA. A total of 874 institutions responded to the survey. The questions ranged from asking for action limits, dosimeter type(s) used, delivery techniques, and actions taken when a plan fails IMRT QA. Results: The most common (52%) planar gamma criteria was 3%/3 mm with a 95% of pixels passing criteria. The most common QA device were diode arrays (48%). The most common first response to a plan failing QA was to re-measure at the same point the point dose (89%), second was to re-measure at a new point (13%), and third was to analyze the plan in relative instead of absolute mode (10%) (Does not add to 100% as not all institutions placed a response for each QA follow-up option). Some institutions, however, claimed that they had never observed a plan failure. Conclusion: The survey provided insights into the way the community currently performs IMRT QA. This information will help in the push to standardize action limits among dosimeters.

60 APPLIED LIFE SCIENCES↗

TU-C-BRE-03: Aggregation of Linac Measurement Data

Purpose: Accurate data of linear accelerator radiation characteristics is important for treatment planning system commissioning as well as regular quality assurance of the machine. The RPC has performed site visits of numerous machines . Data gathered from Varian machines from the past 15 years are presented. The data collected can be used as a secondary check or when commissioning a new machine to verify that values are reasonable. Methods: Data from the past 15 years of RPC site visits was compiled and analyzed. Data was composed from measurements from approximately 400 Varian machines. Each dataset consists of several point measurements at various locations in a water phantom to measure percentage depth dose, output factors, including small MLC fields, off-axis factors, and wedge factors if applicable. Common statistical values are presented for each machine type. Where applicable, data was compared to other reference data given by the vendor or a select number of previous researchers. Results: Data is separated by energy and parameter and then analyzed by machine class. Data distributions of the parameter data were normal except occasionally at the tails. Distributions of the data for each class and parameter are tabulated to give not simply a singular reference value, but metrics about the distribution: 5th and 95th percentile values and the standard deviation as well as the median. Conclusion: The RPC has collected numerous data on Varian linacs and presented the finding of the past 15 years. The data can be used as a reference data set for physicists to compare against. A linac that deviates from the values does not necessarily indicate there is a problem as long as the treatment planning system correlates to the machine. Comparison of linac and treatment planning system data to external reference data can prevent serious treatment errors.

07 ISOTOPE AND RADIATION SOURCES↗

TU-C-BRE-09: Performance Comparisons of Patient Specific IMRT QA Methodologies Using ROC Analysis

Purpose: To evaluate the ability of a selection of patient-specific QA methods to accurately classify IMRT plans as acceptable or unacceptable based on a multiple ion chamber (MIC) phantom. Methods: Twenty-four IMRT plans were selected (20 previously failed the institutional QA), and were measured on a MIC phantom to assess their dosimetric acceptability. These same plans were then measured using film (Kodak EDR2) and ion chamber (Wellhofer cc04), ArcCheck (Sun Nuclear), and MapCheck (Sun Nuclear) (delivered AP field-by-field, AP composite, and with original gantry angles). All gamma analyses were performed at 2%/2mm, 3%/3mm, and 5%/3mm. By using the MIC results as a gold standard, the sensitivity and specificity were calculated across a range of cut-off thresholds (% pixels passing for gamma analysis, and % dose difference for ion chamber), and were used to form ROC curves. Area under the curve (AUC) was used as a metric to quantify the performance of the various QA methods. Results: Grouping device’s AUC’s revealed two statistically significant different groups: ion chamber (AUC of 0.94), AP composite MapCheck (AUC of 0.85), ArcCheck (AUC of 0.84), and film (AUC of 0.82) were in the better performing group, while original gantry angles and AP field-by-field MapCheck (AUC of 0.65 and 0.66, respectively) matched less well with the gold standard results. Optimal cut-offs were also assessed using the ROC curves. We found that while often 90% of pixels passing is used as a criteria, the differing sensitivities of QA methods can lead to device and methodology-based optimal cutoff thresholds. Conclusion: While many methods exist to perform the same task of patient-specific IMRT QA, they utilize different strategies. This work has shown that there are inconsistencies in these methodologies in terms of their sensitivity and specificity to dosimetric acceptability. This work was supported by Public Health Service grants CA010953, CA081647, and CA21661 awarded by the National Cancer Institute, United States Department of Health and Human Services.

60 APPLIED LIFE SCIENCES↗

WE-D-18A-01: Evaluation of Three Commercial Metal Artifact Reduction Methods for CT Simulations in Radiation Therapy Treatment Planning

Purpose: To evaluate three commercial metal artifact reduction methods (MAR) in the context of radiation therapy treatment planning. Methods: Three MAR strategies were evaluated: Philips O-MAR, monochromatic imaging using Gemstone Spectral Imaging (GSI) dual energy CT, and monochromatic imaging with metal artifact reduction software (GSIMARs). The Gammex RMI 467 tissue characterization phantom with several metal rods and two anthropomorphic phantoms (pelvic phantom with hip prosthesis and head phantom with dental fillings), were scanned with and without (baseline) metals. Each MAR method was evaluated based on CT number accuracy, metal size accuracy, and reduction in the severity of streak artifacts. CT number difference maps between the baseline and metal scan images were calculated, and the severity of streak artifacts was quantified using the percentage of pixels with >40 HU error (“bad pixels”). Results: Philips O-MAR generally reduced HU errors in the RMI phantom. However, increased errors and induced artifacts were observed for lung materials. GSI monochromatic 70keV images generally showed similar HU errors as 120kVp imaging, while 140keV images reduced errors. GSI-MARs systematically reduced errors compared to GSI monochromatic imaging. All imaging techniques preserved the diameter of a stainless steel rod to within ±1.6mm (2 pixels). For the hip prosthesis, O-MAR reduced the average % bad pixels from 47% to 32%. For GSI 140keV imaging, the percent of bad pixels was reduced from 37% to 29% compared to 120kVp imaging, while GSI-MARs further reduced it to 12%. For the head phantom, none of the MAR methods were particularly successful. Conclusion: The three MAR methods all improve CT images for treatment planning to some degree, but none of them are globally effective for all conditions. The MAR methods were successful for large metal implants in a homogeneous environment (hip prosthesis) but were not successful for the more complicated case of dental artifacts.

60 APPLIED LIFE SCIENCES↗

SU-C-BRD-07: The Radiological Physics Center (RPC): 45 Years of Improving Radiotherapy Dosimetry

Purpose: The RPC, established in 1968 has contributed to the development, conduct, and QA of NCI funded multi-institutional cooperative group clinical trials and institutions, primarily in the USA/Canada and 242 other countries, participating in trials. Methods: The RPC QA program components were designed to audit the radiation dose calculation chain from the NIST traceable reference beam calibration, to inclusion of dosimetry parameters used to calculate tumor doses, to the delivery of the radiation dose. The QA program included: 1) remote TLD/OSLD audit of machine output, 2) on-site dosimetry review visits, 3) credentialing for advanced technologies, and 4) review of patient treatment records. The RPC presented and published their findings to the radiation oncology community. Results: The number of institutions monitored by the RPC increased from around 1200 in the late 90s, to ∼2000 in 2013. There were over 4000 megavoltage therapy machines and ∼28,000 therapy beams in the 1991 institutions monitored by the RPC by the end of 2013. Within the 14,000 photon, electron and proton beam outputs remotely monitored with TLD/OSLD annually, between 10-20% of the institutions have one or more beams outside the RPC 5% criterion. Dosimetry site visits to photon and proton centers continue to result in 2-4 recommendations affecting key dosimetry parameters that impact patient treatment times. One in four patient treatment records reviewed by the RPC have their dose data corrected by >5% before trial groups use them for outcomes analysis. Twelve of fourteen clinically active proton centers are approved to participate in NCI funded clinical trials. The RPC published 222 peer reviewed articles since 1972. Conclusion: Findings from the RPC suggest that human errors continue to play a role in radiotherapy discrepancies and without the RPC independent QA program, the number of undetected errors and time elapsed before their discovery would have been greater. Work supported by MGH C06 CA059267 and grants CA10953, CA081647 awarded by NCI, DHHS.

60 APPLIED LIFE SCIENCES↗

SU-E-T-110: Development of An Independent, Monte Carlo, Dose Calculation, Quality Assurance Tool for Clinical Trials

Purpose: To develop a comprehensive end-to-end test for Varian's TrueBeam linear accelerator for head and neck IMRT using a custom phantom designed to utilize multiple dosimetry devices. Purpose: To commission a multiple-source Monte Carlo model of Elekta linear accelerator beams of nominal energies 6MV and 10MV. Methods: A three source, Monte Carlo model of Elekta 6 and 10MV therapeutic x-ray beams was developed. Energy spectra of two photon sources corresponding to primary photons created in the target and scattered photons originating in the linear accelerator head were determined by an optimization process that fit the relative fluence of 0.25 MeV energy bins to the product of Fatigue-Life and Fermi functions to match calculated percent depth dose (PDD) data with that measured in a water tank for a 10x10cm2 field. Off-axis effects were modeled by a 3rd degree polynomial used to describe the off-axis half-value layer as a function of off-axis angle and fitting the off-axis fluence to a piecewise linear function to match calculated dose profiles with measured dose profiles for a 40×40cm2 field. The model was validated by comparing calculated PDDs and dose profiles for field sizes ranging from 3×3cm2 to 30×30cm2 to those obtained from measurements. A benchmarking study compared calculated data to measurements for IMRT plans delivered to anthropomorphic phantoms. Results: Along the central axis of the beam 99.6% and 99.7% of all data passed the 2%/2mm gamma criterion for 6 and 10MV models, respectively. Dose profiles at depths of dmax, through 25cm agreed with measured data for 99.4% and 99.6% of data tested for 6 and 10MV models, respectively. A comparison of calculated dose to film measurement in a head and neck phantom showed an average of 85.3% and 90.5% of pixels passing a 3%/2mm gamma criterion for 6 and 10MV models respectively. Conclusion: A Monte Carlo multiple-source model for Elekta 6 and 10MV therapeutic x-ray beams has been developed as a quality assurance tool for clinical trials.

60 APPLIED LIFE SCIENCES↗

SU-E-T-192: FMEA Severity Scores - Do We Really Know?

Purpose: Failure modes and effects analysis (FMEA) is a subjective risk mitigation technique that has not been applied to physics-specific quality management practices. There is a need for quantitative FMEA data as called for in the literature. This work focuses specifically on quantifying FMEA severity scores for physics components of IMRT delivery and comparing to subjective scores. Methods: Eleven physical failure modes (FMs) for head and neck IMRT dose calculation and delivery are examined near commonly accepted tolerance criteria levels. Phantom treatment planning studies and dosimetry measurements (requiring decommissioning in several cases) are performed to determine the magnitude of dose delivery errors for the FMs (i.e., severity of the FM). Resultant quantitative severity scores are compared to FMEA scores obtained through an international survey and focus group studies. Results: Physical measurements for six FMs have resulted in significant PTV dose errors up to 4.3% as well as close to 1 mm significant distance-to-agreement error between PTV and OAR. Of the 129 survey responses, the vast majority of the responders used Varian machines with Pinnacle and Eclipse planning systems. The average years of experience was 17, yet familiarity with FMEA less than expected. Survey reports perception of dose delivery error magnitude varies widely, in some cases 50% difference in dose delivery error expected amongst respondents. Substantial variance is also seen for all FMs in occurrence, detectability, and severity scores assigned with average variance values of 5.5, 4.6, and 2.2, respectively. Survey shows for MLC positional FM(2mm) average of 7.6% dose error expected (range 0–50%) compared to 2% error seen in measurement. Analysis of ranking in survey, treatment planning studies, and quantitative value comparison will be presented. Conclusion: Resultant quantitative severity scores will expand the utility of FMEA for radiotherapy and verify accuracy of FMEA results compared to highly variable subjective scores.

60 APPLIED LIFE SCIENCES↗

SU-E-T-471: Small Field Jaw/MLC Reference Data

Purpose: In recent years the need for small field data of MLCs has increased due to the use of intensity-modulated radiation (IMRT), but moreover the use of stereotactic body radiation (SBRT) has increased, which uses not simply small field sizes, but small jaw and field sizes together. Having reference data for these small fields that is reliable would be invaluable to the physics community. Our study has gathered these values and the data distributions from the Radiological Physics Center's (RPC) site visits between 1990 and the present. Methods: For all measurements, the RPC used a 25 × 25 × 25cm water phantom placed at 100cm SSD. All measurements were made with an Exradin A16 cylindrical ion chamber at an effective depth of 10 cm. A total of 42 Varian machine measurements were used to compose the data for a 6 MV beam and 5 TrueBeam 6 MV flattening filter free (FFF) beams were used for FFF data. Results: Jaw/MLC fields were measured for both 6 MV and 6 MF FFF beams with the jaws and MLCs both at the following field sizes: 6×6, 4×4, 3×3, and 2×2cm. Measurements were normalized to the 10×10 field readings (defined by the jaws and MLC). Spread in the data was minimal and demonstrates a high level of accuracy of acquired data. Conclusion: Small field Jaw/MLC reference data for Varian 6MV and 6 MV FFF beams has been analyzed and presented here, composed of the aggregation of numerous RPC site visits. Obtaining reliable small field data remains difficult, however the RPC has collected high fidelity small field Jaw/MLC data. The data are presented as a reference along with their distributions, in such a way that the physicist can act based upon their own desired agreement with the reference data.

60 APPLIED LIFE SCIENCES↗

SU-E-T-543: Is It Feasible to Tighten the Criteria for IROC's Anthropomorphic Phantoms?

Purpose: To analyze results of IROC Houston QA center's (RPC) H and N and prostate IMRT phantoms to determine the effect that tightening criteria would have on the phantom pass rate. Methods: IROC Houston's anthropomorphic H and N and prostate phantoms are used to credential institution's to participate in NCI clinical trials that allow the use of IMRT. The phantoms are shipped to institutions where they are filled with water and undergo imaging, treatment planning, and irradiation as a patient would. Each phantom houses targets and organs at risk. They also hold film and TLD. Dosimeter results are compared to the institution's treatment plan using the criteria of 7% for PTV TLD doses and ≥85% pixels must pass 7%/4 mm global gamma analyses. Pass rates for the H and N and prostate phantoms were recalculated using the following tighter criteria options: 1) 5% TLD and 85% pixels 7%/4 gamma2) 5% TLD and 90% pixels 7%/4 gamma3) 5% TLD and 85% pixels 5%/4 gammaGamma analysis was repeated for the 30 most recent irradiations of each phantom to estimate results for criteria 3. Results: Pass rates using current criteria for the H and N and prostate phantoms are 84% and 85% respectively. Pass rates since gamma criteria were introduced in 2012 are 90% and 87%. Criteria 1 applied to all irradiations drops pass rates to 78% and 82%. Applying it to only irradiations with gamma results give 77% and 84%. Applying criteria 2 to only phantoms with gamma results drops pass rates to 80% and 74% and they fall to 83% and 67% respectively using criteria 3. Conclusion: Applying tighter criteria to phantom results has potential to increase quality in clinical trials. The results of the 30 most recent irradiations indicate that there may be room to tighten H and N phantom criteria in the future. Work supported by PHS grant CA10953 and CA081647 (NCI, DHHS)

60 APPLIED LIFE SCIENCES↗